Cencora, Inc. $COR Stock: Allspring Global Investments Holdings LLC Decreases Stake

Allspring Global Investments Holdings LLC cut its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 2.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,864 shares of the company’s stock after selling 4,233 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.10% of Cencora worth $59,745,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of COR. M Holdings Securities Inc. purchased a new stake in Cencora in the 3rd quarter worth $786,000. Brighton Jones LLC boosted its holdings in shares of Cencora by 7.7% in the 3rd quarter. Brighton Jones LLC now owns 1,467 shares of the company’s stock worth $441,000 after purchasing an additional 105 shares during the period. Candriam S.C.A. increased its position in Cencora by 15.9% during the third quarter. Candriam S.C.A. now owns 27,379 shares of the company’s stock valued at $8,251,000 after acquiring an additional 3,749 shares during the last quarter. Ethic Inc. grew its holdings in Cencora by 22.0% during the 3rd quarter. Ethic Inc. now owns 9,405 shares of the company’s stock valued at $2,824,000 after purchasing an additional 1,695 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Cencora by 5.5% during the third quarter. Parallel Advisors LLC now owns 7,621 shares of the company’s stock valued at $2,288,000 after buying an additional 395 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.8%

Shares of COR opened at $348.54 on Wednesday. The firm has a market cap of $66.51 billion, a P/E ratio of 19.24, a PEG ratio of 1.79 and a beta of 0.58. The stock’s 50 day moving average is $326.05 and its two-hundred day moving average is $317.23. The company has a current ratio of 0.94, a quick ratio of 0.59 and a debt-to-equity ratio of 3.01. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, topping analysts’ consensus estimates of $4.58 by $0.08. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The company had revenue of $88.35 billion during the quarter, compared to analysts’ expectations of $87.95 billion. During the same period in the prior year, the business posted $3.84 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. Analysts predict that Cencora, Inc. will post 19.58 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be paid a $0.66 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $2.64 annualized dividend and a yield of 0.8%. This is an increase from Cencora’s previous quarterly dividend of $0.60. Cencora’s dividend payout ratio is currently 13.39%.

Analysts Set New Price Targets

Several research firms recently commented on COR. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Leerink Partners raised their price objective on Cencora from $388.00 to $405.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. UBS Group reduced their price target on Cencora from $430.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, October 16th. Bank of America upped their price objective on shares of Cencora from $285.00 to $310.00 in a report on Tuesday, July 21st. Finally, JPMorgan Chase & Co. raised their target price on Cencora from $390.00 to $413.00 and gave the stock an “overweight” rating in a research note on Tuesday. Twelve analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $368.14.

Read Our Latest Stock Report on Cencora

Insider Activity at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the transaction, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.38% of the stock is owned by company insiders.

Cencora Profile

(Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

See Also

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.